United Therapeutics to Co-Develop MannKind's Dry Powder Treprostinil for PAH

United Therapeutics has agreed to license and co-develop MannKind’s clinical-phase dry powder formulation of the pulmonary arterial hypertension (PAH) treatment treprostinil—the active ingredient in United Therapeutics’ top-selling drugs Remodulin® and Tyvaso®—through a collaboration that could generate more than $95 million for MannKind, the companies said today.Under their worldwide exclusive licensing and collaboration agreement, United Therapeutics agreed to o